Pacira BioSciences (PCRX) Non-Current Assets (2010 - 2026)

Pacira BioSciences' Non-Current Assets history runs 17 years deep, the most recent figure standing at $693.6 million for Q1 2026.

• On a quarterly basis, Non-Current Assets fell 16.1% year-over-year to $693.6 million in Q1 2026; TTM through Mar 2026 was $2.9 billion, a 15.64% decrease from a year earlier, with the FY2025 full-year figure at $716.9 million, down 11.31% from the prior year.
• Non-Current Assets eased to $693.6 million in Q1 2026 per PCRX's latest filing, from $716.9 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $1.2 billion in Q1 2022 and bottomed at $693.6 million in Q1 2026.
• The 5-year median for Non-Current Assets is $1.0 billion (2024), against an average of $981.6 million.
• Across the five-year window, Non-Current Assets jumped 126.49% in 2022 and declined 24.05% in 2024, its largest moves.
• Year by year, Non-Current Assets stood at $1.2 billion in 2022, then slipped by 10.02% to $1.1 billion in 2023, then declined by 24.05% to $808.4 million in 2024, then slipped by 11.31% to $716.9 million in 2025, then slipped by 3.26% to $693.6 million in 2026.
• Per Business Quant, the three latest PCRX Non-Current Assets figures stand at $693.6 million (Q1 2026), $716.9 million (Q4 2025), and $734.8 million (Q3 2025).